Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .
Orlistat as an adjunct therapy in type 2 obese diabetic patients treated with sulphonylurea: a Bangladesh experience.
Co-existence of obesity and type 2 DM exacerbates metabolic and other remediable health consequences further . Various pharmacological therapies have been adopted when changing of lifestyle fail to achieve target glycaemic control . Our objective is to find out whether Orlistat can reduce both weight and need for oral hypoglycaemic agent ( OHA ) and improves glycaemic status , lipid disorders , blood pressure in Bangladesh type 2 DM with obesity . In this center , open-label , r and omized , controlled pilot trial 36 type 2 patients with obesity were enrolled . All patients aged 40 - 65 years had BMI > 25 kg/m2 taking sulfonylureas and hypocalorie diet . Twenty one r and omly cases were treated with orlistat 120 mg three times daily for 6 months and 15 without orlistat as control .  Body weight , waist circumferances , fasting blood sugar , HbAlc , serum lipids , blood pressure and dose of drugs were monitored at 0,12 , 24 weeks . After 6 months , orlistat group showed non-significant weight loss than control group ( 3.95 % vs 1.42 % from base lines ) , but showed significant reduction of waist circumference ( 6 % vs 0.63 % , p<0.01 vs p>0.05 from base line ) . Orlistat group had significant improvement in glycaemic status ( HbA1c changes : 22.37 % vs 13.38 % , p<0.001 vs p>0.05 and FBS changes : 21.76 % vs 22.95 % , p<0.01vs p<0.05 ) . Lipid profile had reduced significantly from base lines ( Chol : 19.31 % vs 9.12%,p<0.001vs > 0.05 ; LDL Chol : 24.99 % vs 19.09 % , p<0.001 vs p<0.01 ; Triglyceride : 34.48 % vs 12.61 % , p<0.001 vs p>0.05 ) . Diastolic pressure had improved significantly in orlistat group ( 6.73 % vs 3.70 % , p<0.01 vs > 0.05 ) . Reduction of OHA doses were found in both groups . Thus orlistat can be used as an adjuvant therapy with other OHA in managing glycaemic control , lipid profiles and blood pressure
Orlistat  reduced body weight ( weighted mean difference : −2.12 , p < 0.001 ) , total‐cholesterol ( weighted mean difference : −0.30 mmol/L , p < 0.001 ) , low‐density lipoprotein cholesterol ( weighted mean difference : −0.27 mmol/L , p < 0.001 ) , high‐density lipoprotein cholesterol ( weighted mean difference : −0.034 mmol/L , p < 0.001 ) and triglyceride ( weighted mean difference : −0.09 mmol/L , p < 0.001 ) concentrations , while no effect on lipoprotein(a ) was observed .
Total‐ and low‐density lipoprotein cholesterol‐lowering were associated negatively with duration of orlistat treatment and positively with body weight changes .
In conclusion , Orlistat treatment slightly reduces cholesterol and triglyceride levels , but not lipoprotein(a ) levels .
Total‐ and low‐density lipoprotein cholesterol levels reductions are more consistent in patients with greater body weight reduction and shorter duration of orlistat treatment .
We investigated the efficacy of orlistat on plasma lipids and body weight in a meta‐ analysis of 33 studies including 9732  participants .Orlistat  was associated with a slight but significant decrease in body weight , plasma cholesterol and triglyceride concentrations , whereas plasma Lp(a ) levels were not affected by orlistat treatment .
Greater body weight reduction and lower duration of orlistat treatment promoted more consistent plasma total‐ and LDL‐cholesterol lowering
& NA ; Orlistat , an inhibitor of intestinal lipase , promotes body weight reduction .
The lipid‐lowering efficacy of orlistat is controversial and the effect of orlistat‐induced body weight reduction on lipid changes has not been explored in meta‐regression analyses .
HighlightsOrlistat is an inhibitor of intestinal lipase promoting body weight reduction , but whose lipid‐lowering efficacy is controversial .